Skip to main content

SOM Biotech announces a worldwide license with Corino Therapeutics for its SOM0226 compound against amyloidosis

By 23 de May de 2017November 18th, 2020No Comments
< Back to news
Dr. Raúl Insa, CEO of SOM Biotech (Photo: Barcelona Science Park).

SOM Biotech announces a worldwide license with Corino Therapeutics for its SOM0226 compound against amyloidosis

SOM Biotech, a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases today announces an exclusive worldwide license agreement with U.S. Corino Therapeutics for the clinical development and commercialization of SOM0226, a drug for the treatment of Transthyretin Amyloidosis (ATTR). License was executed after very promising results of the therapeutic agent discovered by SOM –based at the Barcelona Science Park– in a Phase 2a study.


Agreement leverages the strength of Corino development expertise with the breadth of intellectual property and data SOM has already established around SOM0226. License provides SOM with an undisclosed upfront payment, milestones and royalties on product net sales in exchange for the exclusive global rights to the program and includes the use of the drug for all types of ATTR; Familial Amyloid Polyneuropathy, Familial Amyloid Cardiomyopathy, Senile Systemic Amyloidosis, Ophthalmic and CNS forms.

“This license agreement provides a clear validation of the potential of SOM Biotech’s business model. Our repurposing approach can let people suffering from rare diseases ,with no available treatment, have the potential for an expedited development of an alternative treatment since these drugs have been used widely in their original indications” said Dr. Raúl Insa, CEO of SOM. He added that “SOM has found a great management team in Corino that brings substantial strength and expertise to the continued development of the program. This collaboration will allow us to expand our pipeline of treatments within the near future into Phase 2 on two new candidates that we have for other CNS rare conditions”.

“Corino Therapeutics is excited to be working with SOM and their lead program, SOM0226. The preclinical and early clinical results demonstrate the potential to make a significant difference in treating patients with all forms of ATTR,” declared the management of Corino. “We look forward to advancing the development of this promising therapeutic.”

TTR Amyloidosis is a genetic rare degenerative disease that mainly affects the nervous system and heart muscle tissue (myocardium). It originates when the liver and other areas of the organism produce mutations of the protein transthyretin (TTR), which loses their functional structure. This causes toxic aggregates of amyloid fibres to build up, which, depending on the mutation involved, are deposited in different organs, such as brain, kidneys, peripheral nerves, eyes or myocardium, causing them to malfunction and bringing on the various forms of the disease; Familial Amyloid Polyneuropathy (FAP), Familial Amyloid Cardiomyopathy (FAC), Senile Systemic Amyloidosis (SSA), Ophthalmic and CNS forms.

The repurposed therapeutic agent discovered by SOM through its proprietary virtual screening platform has been validated clinically with a Phase 2a study carried out in Barcelona’s Vall d’Hebron hospital. The drug has been granted orphan drug designation by the FDA for all types of ATTR.

Related news [+]